Reversal of Stathmin-Mediated Resistance to Paclitaxel and Vinblastine in Human Breast Carcinoma Cells
Authors:
- Jin-Ming YangJYJin-Ming Yang
- James M. FordJFJames M. Ford
- William N. HaitWHWilliam N. Hait
- 1 May 2007
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 71 (5) , 1233-1240
Abstract
Antimicrotubule agents are commonly used chemotherapy drugs for the treatment of breast and other cancers. However, these agents have variable activity partly because of microtubule regulatory proteins. Stathmin, an 18-kDa phosphoprotein that promotes microtubule depolymerization, was found to be frequently overexpressed in breast cancer. We previously identified stathmin-mediated mechanisms of resistance to antimicrotubule agents, including altered drug binding and delayed transit from G2 into M phase, where these agents are effective in disrupting microtubule dynamics. We hypothesized that by reversing stathmin-mediated depolymerization of microtubules or by promoting entry into mitosis, this could increase sensitivity to antimicrotubule agents in human breast cancer cells overexpressing stathmin. We found that targeting stathmin or wee-1 expression with RNA interference can induce microtubule polymerization and promote G2/M progression, respectively, and sensitize stathmin-overexpressing breast cancer cells to paclitaxel and vinblastine. Furthermore, targeting wee-1 led to the phosphorylation of stathmin, which is known to attenuate its activity. Therefore, these data suggest a novel approach to improving the efficacy of certain antimicrotubule agents against breast cancer by regulating the function of stathmin.Keywords
This publication has 36 references indexed in Scilit:
- Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53Oncogene, 2006
- Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cellsOncogene, 2003
- Quantitative RT-PCR reveals a ubiquitous but preferentially neural expression of the KIS gene in rat and humanMolecular Brain Research, 2003
- The oncoprotein 18/stathmin family of microtubule destabilizersCurrent Opinion in Cell Biology, 2002
- Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 inductionOncogene, 1999
- Overexpression of the stathmin gene in a subset of human breast cancerBritish Journal of Cancer, 1998
- Phenotypic analysis of ovarian carcinoma: Polypeptide expression in benign, borderline and malignant tumorsInternational Journal of Cancer, 1997
- The Stathmin/Tubulin Interaction in VitroJournal of Biological Chemistry, 1997
- Identification of a Protein That Interacts with Tubulin Dimers and Increases the Catastrophe Rate of MicrotubulesCell, 1996
- Regulation of Cdc2 activity by phosphorylation at T14/Y151996